Vicarious Surgical Inc. ( (RBOT) ) has released its Q3 earnings. Here is a breakdown of the information Vicarious Surgical Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Vicarious Surgical Inc. is a pioneering robotics technology company focused on enhancing surgical procedures through innovative robotic systems, primarily operating in the medical technology sector. The company is known for its unique approach to minimally invasive surgery using human-like surgical robots.
In its third-quarter 2025 financial report, Vicarious Surgical highlighted significant progress in its operational strategies, including a reduction in operating expenses and a successful capital raise. The company reported a decrease in its net loss compared to the previous year, reflecting improved financial discipline and strategic execution.
Key financial metrics from the report show a 35% reduction in total operating expenses, with research and development costs down by 26% and general and administrative expenses reduced by 45%. The company’s net loss also decreased from $17.1 million in Q3 2024 to $11.1 million in Q3 2025. Additionally, Vicarious Surgical successfully raised $5.9 million in a direct offering, bolstering its financial position.
Looking ahead, Vicarious Surgical remains focused on maintaining its development timelines and reducing its cash burn rate, with expectations to limit its full-year 2025 cash burn to approximately $50 million. The company continues to advance its innovative surgical technologies, aiming to enhance patient outcomes and drive growth in the medical robotics field.